FLT3 and acute myeloid leukemia: The demonstrated sustained responses to imetelstat in NRAS-mutant AML patient samples raise the possibility that imetelstat may be used as salvage therapy or possibly in combination with FLT3 inhibitors or venetoclax to prolong remission and prevent relapse.